ATE239073T1 - INHIBITION OF TUMOR CELL GROWTH BY ADMINISTRATION OF B7 TRANSFIED CELLS - Google Patents

INHIBITION OF TUMOR CELL GROWTH BY ADMINISTRATION OF B7 TRANSFIED CELLS

Info

Publication number
ATE239073T1
ATE239073T1 AT93307816T AT93307816T ATE239073T1 AT E239073 T1 ATE239073 T1 AT E239073T1 AT 93307816 T AT93307816 T AT 93307816T AT 93307816 T AT93307816 T AT 93307816T AT E239073 T1 ATE239073 T1 AT E239073T1
Authority
AT
Austria
Prior art keywords
cells
tumor cells
tumor cell
cell growth
transfied
Prior art date
Application number
AT93307816T
Other languages
German (de)
Inventor
Lieping Chen
Ingegerd Hellstroem
Karl Erik Hellstroem
Jeffrey A Ledbetter
Peter S Linsley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE239073T1 publication Critical patent/ATE239073T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to a method of inhibiting tumor cell growth. Tumor cells from a pateint are recombinantly engineered to express the B7 surface protein and these cells are then readminsistered to the pateint. The presence of the B7 molecule on the tumor cell surface stimulates a broad immunologic response against both the B7-transfected and non-transfected tumor cells and results in the immunologic killing of localized and metastatic tumor cells. B7 transfection of the tumor cells, or cell membranes, serves as a stimulant to engender a potent immunologic response against the surface antigens present on the tumor cells. <IMAGE>
AT93307816T 1992-10-02 1993-10-01 INHIBITION OF TUMOR CELL GROWTH BY ADMINISTRATION OF B7 TRANSFIED CELLS ATE239073T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95612392A 1992-10-02 1992-10-02
US610293A 1993-01-15 1993-01-15

Publications (1)

Publication Number Publication Date
ATE239073T1 true ATE239073T1 (en) 2003-05-15

Family

ID=26675186

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93307816T ATE239073T1 (en) 1992-10-02 1993-10-01 INHIBITION OF TUMOR CELL GROWTH BY ADMINISTRATION OF B7 TRANSFIED CELLS

Country Status (11)

Country Link
US (1) US6183734B1 (en)
EP (1) EP0600591B1 (en)
JP (1) JP3837169B2 (en)
AT (1) ATE239073T1 (en)
AU (1) AU662450B2 (en)
CA (1) CA2107537C (en)
DE (1) DE69332921T2 (en)
DK (1) DK0600591T3 (en)
ES (1) ES2197147T3 (en)
MX (1) MX9306147A (en)
PT (1) PT600591E (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5056137A (en) * 1989-09-27 1991-10-08 Sills Richard R Method and apparatus for encoding and decoding signals
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
WO1996021015A2 (en) * 1994-12-30 1996-07-11 Chiron Corporation Combination gene delivery vehicles
CA2172436A1 (en) * 1995-03-23 1996-09-24 Lieping Chen Compositions and methods for increasing the immunogenicity of tumor cells
WO1996034952A1 (en) * 1995-05-04 1996-11-07 Boehringer Ingelheim International Gmbh Expression of tap and lmp in tumour cells
DE19516040A1 (en) * 1995-05-04 1996-11-07 Boehringer Ingelheim Int Increasing immune response to tumour cells by increasing expression of TAP or LMP proteins
SE9604581D0 (en) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6682741B1 (en) * 1998-06-10 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services β2 microglobulin fusion proteins and high affinity variants
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
US20030096016A1 (en) * 2001-09-07 2003-05-22 Yeda Research And Development Co. Ltd. Methods of kidney transplantation utilizing developing nephric tissue
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
AU2003234469A1 (en) * 2002-05-02 2003-11-17 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2463464A1 (en) * 2003-04-28 2004-10-28 Auckland Uniservices Limited Methods of treatment and compositions therefor
CA2463487A1 (en) * 2003-04-28 2004-10-28 Auckland Uniservices Limited Tumours treating combinations, compositions and methods
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000092A1 (en) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
EP0600591B1 (en) 2003-05-02
DE69332921D1 (en) 2003-06-05
DE69332921T2 (en) 2004-05-19
CA2107537C (en) 2007-01-30
MX9306147A (en) 1994-06-30
JPH0769928A (en) 1995-03-14
CA2107537A1 (en) 1994-04-03
AU662450B2 (en) 1995-08-31
ES2197147T3 (en) 2004-01-01
EP0600591A3 (en) 1995-03-01
AU4877293A (en) 1994-04-14
US6183734B1 (en) 2001-02-06
PT600591E (en) 2003-09-30
DK0600591T3 (en) 2003-08-25
JP3837169B2 (en) 2006-10-25
EP0600591A2 (en) 1994-06-08

Similar Documents

Publication Publication Date Title
DE69332921D1 (en) Inhibition of tumor cell growth by administration of B7-transfected cells
DE69333802T8 (en) OUTER MEMBRANE PROTEIN FROM HAEMOPHILUS
HUP9904023A2 (en) Use of leptin antagonists for treating insulin resistance in type ii diabetes
DE69534995D1 (en) VARIANTS OF ANTIGENES OF THE HUMAN PAPILLOMY VIRUS
NO934310L (en) Procedure for Preparation of Whey Protein Hydrolyzate
DE69941165D1 (en) CD40 binding molecules and CTL peptides for the treatment of tumors
NO961115D0 (en) Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds
DE69829668D1 (en) PREPARATION AND USE OF RECOMBINANT INFLUENZA A VIRUS M2 CONSTRUCTIONS AND IMPORTS
FR2643817B1 (en) PHARMACEUTICAL COMPOSITION, USEFUL AS A PREVENTIVE OR CURATIVE AGAINST TUMORS INDUCED BY PAPILLOMAVIRUS
BR9712556A (en) Plasmid, pharmaceutical composition, and, process of immunizing an individual against an antigen
DE69839489D1 (en) VACCINATE FOR PREVENTING OR BZW. TREATMENT OF HEPATITIS C
DE3884316D1 (en) Synthetic peptides, antibodies directed against them and their use.
FI924222A0 (en) GP75 SOM ETT TUMOERVACCIN MOT MELANOMA.
EA200100395A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING ANTIGENIC PROTEIN COATING ANTI-ANTITROTHAL EFFECT
KR890006253A (en) Vaccines against E. coli septicaemia in poultry
DE69301733D1 (en) Vaccines against metazoan parasites
MacKintosh et al. Proteins synthesized before and after fertilization in sea urchin eggs
DE59208025D1 (en) NEW THROMBINE INHIBITORIC PROTEINS FROM LAND BLOOD GELS
DK0938329T3 (en) Immunogenic TLP composition
DE69330246D1 (en) VACCINE SUBSTANCES BASED ON STREPTOKINASE
MX9601071A (en) Compositions and methods for increasing the immunogenicity of tumor cells.
Samson et al. The kinetics of colicin E3 induced fragmentation of Escherichia coli 16S ribosomal RNA in vivo
DK0542895T3 (en) Cross-reactive influenza A immunization
DE59611353D1 (en) TRANSKETOLASE-RELATED PROTEIN
IT8647546A0 (en) TRANSDERMAL INFUSION SYSTEM OF DRUGS IN THE GENITAL AREA TO CREATE, IMPROVE AND/OR CORRECT THE SEXUAL EXCITATION OF THE HUMAN SPECIES

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0600591

Country of ref document: EP